Latest News

Weekly News Roundup | 16 November 2026

Weekly News Roundup | 16 November 2026

Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention. Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in...

read more

Latest News

ZW209 Licensing Deal: What Does Roche Get From Zymeworks?

ZW209 Licensing Deal: What Does Roche Get From Zymeworks?

Under the ZW209 licensing deal with Zymeworks, Roche will receive exclusive global rights to develop and commercialise ZW209. In return, Zymeworks is due $55 million upfront and $40 million when a Phase 1b trial begins. It is also eligible for up to $718 million in...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Avacopan UK Suspension Follows Retracted Trial Data

Avacopan UK Suspension Follows Retracted Trial Data

The avacopan UK suspension took effect on 1 September 2026. The Medicines and Healthcare products Regulatory Agency stopped supply of the medicine to new patients that day. It also signalled its intention to revoke the UK marketing authorisation on 1 March 2027. The...

read more
What a Hospitalist’s Floor Sees That Health AI Doesn’t

What a Hospitalist’s Floor Sees That Health AI Doesn’t

Two rooms that rarely talk I spend my working life in two rooms that almost never talk to each other. The first is the hospital floor, where I care for several thousand patients a year as an attending physician. The second is the conference room, where I evaluate...

read more
Licensing versus Acquisition: How Pharma Chooses

Licensing versus Acquisition: How Pharma Chooses

On 26 August 2026, SK Biopharmaceuticals agreed to license an epilepsy platform from Biohaven. Sixteen days earlier, Jazz Pharmaceuticals agreed to buy an epilepsy biotech outright. Same disease area, same month, two opposite structures. The licensing versus...

read more
ADHD Management for the Entire Active Day is Within Reach

ADHD Management for the Entire Active Day is Within Reach

When you’re a child, leaving an amusement park after a wondrous day is hard. Adults know a similar feeling after a vacation or the finale of a favorite television series. Of course, it’s always disappointing when an enjoyable experience runs out. Still, the stakes are...

read more
Weekly News Roundup | 31 August 2026

Weekly News Roundup | 31 August 2026

Life science news 31 August 2026: three US approvals, two UK device safety alerts and two licensing deals. Revolution Medicines won approval for a broad RAS-targeted pancreatic cancer drug. AstraZeneca and Ionis presented the full data behind a closely watched heart...

read more
Avacopan UK Suspension Follows Retracted Trial Data

Avacopan UK Suspension Follows Retracted Trial Data

The avacopan UK suspension took effect on 1 September 2026. The Medicines and Healthcare products Regulatory Agency stopped supply of the medicine to new patients that day. It also signalled its intention to revoke the UK marketing authorisation on 1 March 2027. The...

read more
What a Hospitalist’s Floor Sees That Health AI Doesn’t

What a Hospitalist’s Floor Sees That Health AI Doesn’t

Two rooms that rarely talk I spend my working life in two rooms that almost never talk to each other. The first is the hospital floor, where I care for several thousand patients a year as an attending physician. The second is the conference room, where I evaluate...

read more
Licensing versus Acquisition: How Pharma Chooses

Licensing versus Acquisition: How Pharma Chooses

On 26 August 2026, SK Biopharmaceuticals agreed to license an epilepsy platform from Biohaven. Sixteen days earlier, Jazz Pharmaceuticals agreed to buy an epilepsy biotech outright. Same disease area, same month, two opposite structures. The licensing versus...

read more
ADHD Management for the Entire Active Day is Within Reach

ADHD Management for the Entire Active Day is Within Reach

When you’re a child, leaving an amusement park after a wondrous day is hard. Adults know a similar feeling after a vacation or the finale of a favorite television series. Of course, it’s always disappointing when an enjoyable experience runs out. Still, the stakes are...

read more
Weekly News Roundup | 31 August 2026

Weekly News Roundup | 31 August 2026

Life science news 31 August 2026: three US approvals, two UK device safety alerts and two licensing deals. Revolution Medicines won approval for a broad RAS-targeted pancreatic cancer drug. AstraZeneca and Ionis presented the full data behind a closely watched heart...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Clinical Trials Roundup | 28 Aug 2026

Clinical Trials Roundup | 28 Aug 2026

Revolution Medicines’ Rasonque receives FDA approval as what the FDA calls the first in class targeted therapy for metastatic pancreatic cancer, Priovant’s Lisraya is cleared as the first oral therapy indicated for dermatomyositis in adults, Johnson & Johnson’s...

read more
From EHR Data to Real-World Evidence: Health IT Meets R&D

From EHR Data to Real-World Evidence: Health IT Meets R&D

For most of their existence, electronic health records have been treated as administrative infrastructure, a place to document a visit, justify a claim and satisfy a compliance requirement. That framing no longer reflects their potential. The same records that...

read more
Oral GLP-1 Manufacturing: Can Supply Meet Demand?

Oral GLP-1 Manufacturing: Can Supply Meet Demand?

Oral GLP-1 manufacturing is now the binding constraint in obesity, not patient acceptance. The question is peptide capacity, tabletting lines and capital committed ahead of demand. Two weight loss tablets have reshaped the obesity market in under a year. Novo...

read more

Further News

Newly Diagnosed Glioblastoma Trial Misses Primary Survival Endpoint

MimiVax and Roswell Park Comprehensive Cancer Center reported topline Phase 2b data on 7 October 2026. The SURVIVE trial tested the survivin peptide vaccine SurVaxM in newly diagnosed glioblastoma. The primary endpoint was overall survival. The full study population...

Digital Twins Need a New Validation Trigger: Drift, Not Deployment

A digital twin commissioned to mirror a manufacturing process is, by design, built to keep learning. It ingests live sensor data, recalibrates its internal parameters, and narrows the gap between what it predicts and what the physical process is actually doing. That's...

Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.

In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...

Traditional Botanical Knowledge: A Research Lead, Not a Health Claim

I like to call myself a conduit between ancient healing wisdom and modern life. I came to the US thirty years ago to be trained as a pathologist, but I grew up among generations of herbalists. My family roots and my research background have shaped how I view the...

Digital Validation in Life Sciences: CSA, Annex 11 and Annex 22 in 2026

For most of the past three decades, validating a computerised system in a GMP facility has usually meant paper. Teams compiled binders of test scripts, wet-ink signatures and printed screenshots. That model is now under pressure, and digital validation in life...

The Future of Diagnostics Is Molecularly Precise

The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...

EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint

ArriVent’s FURVENT Phase 3 missed its primary endpoint in EGFR exon 20 insertion lung cancer. LSDN examines the UK access position.

    Healthcare AI Needs Trusted Evidence and Communication Standards

    The resignation of Anthropic researcher Jacob Coxon has brought renewed attention to the risks of increasingly powerful artificial intelligence. According to the Associated Press, Coxon warned that competitive pressure was overtaking safety considerations at leading...

    Younger TAVR Patients Raise the Bar for Long-Term Valve Performance

    As transcatheter aortic valve replacement (TAVR) expands into younger patients with longer life expectancy, the definition of a successful procedure needs to grow with it. A July 2026 international position statement identified this trend as a reason for greater focus...

    Biotech Deal Structure: Upfronts, Milestones and Royalties Explained

    On 2 October 2026, Novartis agreed to license an autoimmune candidate from Abogen for $575 million upfront. Abogen’s release said milestones could add up to about $7.2 billion if every option is exercised. Many headlines led with the combined figure of about $7.8...

    Lower Drug Prices Mean Little If the Medication Can’t Reach the Resident

    The debate over prescription drug costs, in long-term care as elsewhere, often starts and ends with a number. How much did the medication cost before a negotiated price? How much will Medicare pay? What will the patient owe at the pharmacy counter? Those are important...

    Pneumococcal Conjugate Vaccine Meets Phase 3 Goals, Two Serotypes Lag

    Vaxcyte’s 31-valent pneumococcal conjugate vaccine met every primary endpoint in OPUS-1. It fell short on two serotypes against Capvaxive, and it meets a British adult programme that changed product this year.

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.